Viropro Company Leadership
Viropro employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 34 years, averaging almost 11.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Viropro's management performance can provide insight into the firm performance.
| Michelle Peake CEO Director and CEO of Alpha Biologics Sdn. Bhd |
| Bruce Cohen Chairman Chairman of the Board |
Viropro Management Team Effectiveness
As of the 28th of December 2025, Return On Tangible Assets is likely to drop to -4.04. In addition to that, Return On Capital Employed is likely to grow to -0.58. At this time, Viropro's Total Assets are very stable compared to the past year. As of the 28th of December 2025, Fixed Asset Turnover is likely to grow to 16.32, while Net Tangible Assets are likely to drop (508.4 K). Viropro's management efficiency ratios could be used to measure how well Viropro manages its routine affairs as well as how well it operates its assets and liabilities.As of the 28th of December 2025, Net Loss is likely to drop to about (1.2 M)
Viropro Workforce Comparison
Viropro is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,340. Viropro adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Viropro Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viropro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viropro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Viropro insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Beausoleil Serge over a year ago Sale by Beausoleil Serge of 1662500 shares of Viropro |
Viropro Notable Stakeholders
A Viropro stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Viropro often face trade-offs trying to please all of them. Viropro's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Viropro's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michelle Peake | Director and CEO of Alpha Biologics Sdn. Bhd | Profile | |
| Bruce Cohen | Chairman of the Board | Profile | |
| Jeff Hale | Chief Bus. Officer | Profile |
About Viropro Management Performance
The success or failure of an entity such as Viropro often depends on how effective the management is. Viropro management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Viropro management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Viropro management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.85) | (4.04) | |
| Return On Capital Employed | (0.62) | (0.58) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.62) | (0.66) |
Viropro Workforce Analysis
Traditionally, organizations such as Viropro use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Viropro within its industry.Viropro Manpower Efficiency
Return on Viropro Manpower
| Revenue Per Employee | 190.4K | |
| Revenue Per Executive | 190.4K | |
| Net Loss Per Employee | 336.7K | |
| Net Loss Per Executive | 336.7K |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viropro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viropro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Revenue Growth 1.19 |
The market value of Viropro is measured differently than its book value, which is the value of Viropro that is recorded on the company's balance sheet. Investors also form their own opinion of Viropro's value that differs from its market value or its book value, called intrinsic value, which is Viropro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viropro's market value can be influenced by many factors that don't directly affect Viropro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viropro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.